Actavis has reached attractive entry point, says RBC Capital After meeting with Actavis' (ACT) management, RBC Capital thinks there are several reasons to feel good about the company's near-term outlook. The firm adds that investors will better appreciate the strategic value in the Actavis and Forest Labs (FRX) platform over time, while Actavis' management spent a great deal of time talking about M&A. The firm keeps a Top Pick and $259 price target on Actavis.
News For ACT;FRX From The Last 14 Days
Check below for free stories on ACT;FRX the last two weeks.